Motif Bio (MTFB) shares rallied after it announced on Thursday that the U.S. Army will be funding a research project to evaluate Motif Bio’s lead product Iclaprim and a new aerosol technology.
The research project will evaluate the potential of using a new drug-device combination for wound care and to prevent and treat wound infections on the battlefield.
It will use a new aerosol technology that delivers antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery, in combination with Iclaprim.
Motif Bio’s Iclaprim is designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.
The Walter Reed Army Institute of Research (WRAIR) and Motif Bio will conduct pre-clinical testing on new combinations with Iclaprim to improve safety and efficacy administered by the new enhanced aerosol technology.
The U.S. Department of Defense will be funding the research through the Congressionally Directed Military Infectious Diseases Research Program.
Shares in Motif Bio were trading 26.6% higher at 0.798p in early Thursday morning trading
The work will be led by Dr. Daniel Zurawski, Ph.D., Chief, Pathogenesis and Virulence, WRAIR/Wound Infections Dept./Bacterial Diseases Branch.
David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible.”
“The data generated from Dr. Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."
Follow News & Updates from Motif Bio here: